Janssen Pharmaceutica Nv

Jannsen Pharmaceutica Bv

Solent Therapeutics, LLC

Alison L Chambers

Wei Xiao

J Guy Breitenbucher

John M Keith

Natalie Anne Hawryluk

Jeffrey E Merit

Mark S Tichenor

William Moore Jones

Mark Seierstad

Amy K Timmons

Neelakandha S Mani

Masaki Seto

Xiaohu Deng

Richard Apodaca

Mitsunori Kono

Zenyu Shiokawa

Tony Gibson

Angie Vassar

Steve Swann

Joan M Pierce

Simone Bigi

Mark J Sierestad

Jason Pickens

Feng Zhou

Disclosed are compounds of Formula (1), tautomers thereof, and pharmaceutically acceptable salts of the compounds or tautomers, wherein L, R, R, R, Rand Rare defined in the specification. This disclosure also relates to materials and methods for preparing compounds of Formula (1), to pharmaceutical compositions which contain them, and to their use for treating diseases, disorders or conditions associated with MRGX2.

3-amino-4H-benzo[e][1,2,4]thiadiazine 1,1-dioxide derivatives as inhibitors of MRGX2

Certain ethylene diamine compounds of Formula (I) are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed. 

Ethylene diamine modulators of fatty acid hydrolase

Certain aryl-substituted heterocyclic urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis).

Aryl-substituted heterocyclic urea modulators of fatty acid amide hydrolase

Certain heteroaryl-substituted piperidinyl and piperazinyl urea compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, insulin resistance, diabetes, osteoporosis, and movement disorders (e.g., multiple sclerosis).

Heteroaryl-substituted urea modulators of fatty acid amide hydrolase

Certain aryl-hydroxyethylamino-pyrimidine and triazine compounds are described, which are useful as FAAH inhibitors. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity, such as anxiety, pain, inflammation, sleep disorders, eating disorders, energy metabolism disorders, and movement disorders (e.g., multiple sclerosis). Methods of synthesizing such compounds are also disclosed.

Aryl-hydroxyethylamino-pyrimidines and triazines as modulators of fatty acid amide hydrolase

Growing community of inventors

San Diego, CA, United States of America

Alison L Chambers